Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

12,500 cancer patients studied: which heart attack strategy saves more lives?

NCT ID NCT06702436

Knowledge-focused Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This completed study looked at 12,500 cancer patients who had a type of heart attack called NSTEMI. Researchers compared those who got invasive procedures like angiography versus those treated only with medications. The goal was to see which approach led to fewer deaths in the hospital and shorter stays.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the results show a clear benefit of one strategy, it could guide doctors in choosing the best heart attack treatment for cancer patients.
What could go wrong
As an observational study, it cannot prove cause and effect. Differences in patient health or cancer type may influence outcomes, not just the treatment chosen.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

12,500 people

The number who actually took part.

Started

Jun 2024

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will include adult patients aged 18 and older, diagnosed with cancer and hospitalized for non-ST elevation myocardial infarction (NSTEMI). Both males and females with various cancer types will be eligible, and the study will focus on those receiving either invasive or conservative treatment for NSTEMI. Patients with severe comorbidities, such as end-stage diseases or missing critical data, will be excluded. The study aims to assess the impact of invasive versus conservative treatment strategies on mortality, re-hospitalization, and cardiovascular events in this cohort, which is often underrepresented in clinical trials. This population will help understand optimal treatment approaches for cancer patients with NSTEMI.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age: Patients aged 18 years and older. * Diagnosis: Patients with a confirmed cancer diagnosis. * Acute Condition: Patients diagnosed with non-ST elevation myocardial infarction (non-ST MI). * Treatment: Patients who received either invasive treatment (including coronary angiography and revascularization) or conservative (pharmacological) treatment for non-ST MI. * Consent: Patients who have provided informed consent or are part of a retrospective study where consent is waived. Exclusion Criteria: * Age: Patients younger than 18 years. * Non-cancer diagnoses: Patients without a cancer diagnosis. * ST-Elevation Myocardial Infarction: Patients with ST elevation myocardial infarction (STEMI) instead of non-ST elevation myocardial infarction (NSTEMI). * Pre-existing severe comorbidities: Patients with severe or terminal comorbidities (e.g., end-stage liver disease, end-stage renal disease, or severe cognitive impairment) that would confound the outcomes. * Incomplete medical records: Patients with missing data on relevant clinical variables (e.g., GRACE score, treatment received, or mortality data). * Pregnancy: Pregnant patients, as their conditions may complicate the interpretation of results. * Inability to provide informed consent: Patients unable to provide informed consent (if applicable).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute subendocardial myocardial infarction cancer myocardial infarction neoplasm Non-ST Elevated Myocardial Infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myocardial infarction

Contacts and locations

Locations

  • Ankara Oncology Training and Research Hospital

    Ankara, Ankara, 06200, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.